Yu-Li Wang
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Interests
Yu-Li Wang has a total of 11 co-authors. Here are the top co-authors by number of shared publications:
- Changyu Liu
Pathology Laboratory, Tianjin University of Traditional Chinese Medicine, College of Integrative Chinese and Western Medicine, Tianjin, China
1 shared publication - Chao-Min Cheng
National Tsing Hua University
1 shared publication - Ching-Fen Shen
Department of Pediatrics, National Cheng Kung University Hospital, College of Medicine, National Cheng Kung University, Tainan 701, Taiwan
1 shared publication - Jiaqi Zhang
College of Integrative Medicine, Tianjin University of Traditional Chinese Medicine, Tianjin, China
1 shared publication Lili Song
College of Integrative Medicine, Tianjin University of Traditional Chinese Medicine, Tianjin, China
1 shared publicationMaojuan Guo
College of Integrative Medicine, Tianjin University of Traditional Chinese Medicine, Tianjin, China
1 shared publication
Latest Publications
- 1 July 2024
- Published by Bentham Science Publishers Ltd. in Current Topics in Medicinal Chemistry
- Vol. 24 (17) , 1451-1463
CircRNA Interference Pathway: A New Target for Intervention in Different Stages of Heart Failure
Cardio-cerebrovascular disease has seen a rapid rise in recent years, with Heart Failure (HF) -- a terminal stage of various cardiovascular diseases -- also on the rise. HF has a complex pathogenesis involving multiple factors, such as inflammation, fibrosis, and oxidative stress. Due to its unique reverse shear mechanism, HF exhibits distinct expression patterns across different diseases. CircRNA has been linked to conditions like cancer, diabetes, and osteoarthritis. This article briefly introduces the mechanisms of circRNA biogenesis and its associated biological functions, focusing on CircSLC8A1-1, CircRNA_000203, and others at the early stage of HF, CircRNA PAN3, CircRNA (ACR), and others during the progression of HF, and CircHIPK3, CircNfix, and others at the end stage of HF. These circRNAs play a participatory role in the exact mechanism. As a research method, circRNA can be utilized to study the pathogenesis of heart failure and serve as a target for drug discovery and development. Therefore, circRNA's ability to mark the disease at different stages has significant guiding implications for HF monitoring, treatment, and prognosis.
- 1 July 2024
- Published by Bentham Science Publishers Ltd. in Current Topics in Medicinal Chemistry
- Vol. 24 (17) , 1451-1463
CircRNA Interference Pathway: A New Target for Intervention in Different Stages of Heart Failure
Cardio-cerebrovascular disease has seen a rapid rise in recent years, with Heart Failure (HF) -- a terminal stage of various cardiovascular diseases -- also on the rise. HF has a complex pathogenesis involving multiple factors, such as inflammation, fibrosis, and oxidative stress. Due to its unique reverse shear mechanism, HF exhibits distinct expression patterns across different diseases. CircRNA has been linked to conditions like cancer, diabetes, and osteoarthritis. This article briefly introduces the mechanisms of circRNA biogenesis and its associated biological functions, focusing on CircSLC8A1-1, CircRNA_000203, and others at the early stage of HF, CircRNA PAN3, CircRNA (ACR), and others during the progression of HF, and CircHIPK3, CircNfix, and others at the end stage of HF. These circRNAs play a participatory role in the exact mechanism. As a research method, circRNA can be utilized to study the pathogenesis of heart failure and serve as a target for drug discovery and development. Therefore, circRNA's ability to mark the disease at different stages has significant guiding implications for HF monitoring, treatment, and prognosis.
- Open Access
- 1 January 2023
- Published by XMLink in Clinical and Experimental Vaccine Research
- Vol. 12 (4) , 337-345
Impact of the COVID-19 vaccine booster strategy on vaccine protection: a pilot study of a military hospital in Taiwan
Wang YL, et al. Clin Exp Vaccine Res. 2023 Oct;12(4):337-345. https://doi.org/10.7774/cevr.2023.12.4.337
- 1 January 2023
- Published by XMLink in Clinical and Experimental Vaccine Research
- Vol. 12 (4) , 337-345
Open AccessImpact of the COVID-19 vaccine booster strategy on vaccine protection: a pilot study of a military hospital in Taiwan
Wang YL, et al. Clin Exp Vaccine Res. 2023 Oct;12(4):337-345. https://doi.org/10.7774/cevr.2023.12.4.337